A detailed history of Price T Rowe Associates Inc transactions in Omeros Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 35,181 shares of OMER stock, worth $362,716. This represents 0.0% of its overall portfolio holdings.

Number of Shares
35,181
Previous 35,181 -0.0%
Holding current value
$362,716
Previous $143,000 2.1%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$2.88 - $4.89 $6,474 - $10,992
2,248 Added 6.83%
35,181 $122,000
Q4 2023

Feb 14, 2024

BUY
$1.08 - $3.63 $1,841 - $6,189
1,705 Added 5.46%
32,933 $108,000
Q3 2023

Nov 14, 2023

BUY
$2.81 - $5.69 $3,591 - $7,271
1,278 Added 4.27%
31,228 $92,000
Q2 2023

Aug 14, 2023

BUY
$4.45 - $7.57 $34,487 - $58,667
7,750 Added 34.91%
29,950 $163,000
Q1 2023

May 15, 2023

SELL
$2.48 - $5.22 $20,832 - $43,848
-8,400 Reduced 27.45%
22,200 $104,000
Q4 2022

Feb 14, 2023

BUY
$1.75 - $3.96 $22,750 - $51,480
13,000 Added 73.86%
30,600 $69,000
Q2 2022

Aug 15, 2022

SELL
$1.92 - $6.28 $10,089 - $33,001
-5,255 Reduced 22.99%
17,600 $48,000
Q1 2022

May 16, 2022

BUY
$5.07 - $7.2 $42,081 - $59,760
8,300 Added 57.03%
22,855 $137,000
Q4 2021

Feb 14, 2022

SELL
$5.67 - $8.54 $102,627 - $154,573
-18,100 Reduced 55.43%
14,555 $94,000
Q2 2021

Aug 16, 2021

SELL
$14.81 - $19.13 $20,600 - $26,609
-1,391 Reduced 4.09%
32,655 $485,000
Q1 2021

May 17, 2021

BUY
$14.52 - $23.53 $217 - $352
15 Added 0.04%
34,046 $606,000
Q4 2020

Feb 16, 2021

BUY
$10.14 - $15.19 $345,074 - $516,930
34,031 New
34,031 $486,000

Others Institutions Holding OMER

About OMEROS CORP


  • Ticker OMER
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,730,000
  • Market Cap $647M
  • Description
  • Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical program...
More about OMER
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.